Vertex Pharmaceuticals (VRTX) EBT Margin (2009 - 2026)

Vertex Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 41.95% for Q1 2026.

• In Q1 2026, EBT Margin rose 1558.0% year-over-year to 41.95%; the TTM figure through Mar 2026 stood at 42.28% (up 4498.0% YoY), while the FY2025 annual figure was 38.69%, up 3643.0% from the prior year.
• EBT Margin for Q1 2026 stood at 41.95%, up from 41.72% in the prior quarter.
• The five-year high for EBT Margin was 50.4% in Q3 2022, with the low at 128.18% in Q2 2024.
• The 5-year median for EBT Margin is 44.16% (2024), against an average of 33.21%.
• The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 17477 bps in 2024, then jumped 17146 bps in 2025.
• Vertex Pharmaceuticals' EBT Margin stood at 46.76% in 2022, then fell by 3 bps to 45.58% in 2023, then dropped by 14 bps to 39.03% in 2024, then climbed by 7 bps to 41.72% in 2025, then gained by 1 bps to 41.95% in 2026.
• Business Quant data shows VRTX's EBT Margin at 41.95% in Q1 2026, 41.72% in Q4 2025, and 42.22% in Q3 2025.